120 related articles for article (PubMed ID: 36877527)
1. Vincristine and dexamethasone pulses in addition to maintenance therapy among pediatric acute lymphoblastic leukemia (GD-ALL-2008): An open-label, multicentre, randomized, phase III clinical trial.
Qiu KY; Wang JY; Huang LB; Li CG; Xu LH; Liu RY; Chen HQ; Ruan YS; Zhen ZJ; Li CK; Fang JP
Am J Hematol; 2023 Jun; 98(6):869-880. PubMed ID: 36877527
[TBL] [Abstract][Full Text] [Related]
2. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial.
Yang W; Cai J; Shen S; Gao J; Yu J; Hu S; Jiang H; Fang Y; Liang C; Ju X; Wu X; Zhai X; Tian X; Wang N; Liu A; Jiang H; Jin R; Sun L; Yang M; Leung AWK; Pan K; Zhang Y; Chen J; Zhu Y; Zhang H; Li C; Yang JJ; Cheng C; Li CK; Tang J; Zhu X; Pui CH
Lancet Oncol; 2021 Sep; 22(9):1322-1332. PubMed ID: 34329606
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia.
Nagatoshi Y; Matsuzaki A; Suminoe A; Inada H; Ueda K; Kawakami K; Yanai F; Nakayama H; Moritake H; Itonaga N; Hotta N; Fujita K; Hidaka Y; Yamanaka T; Kawano Y; Okamura J
Pediatr Blood Cancer; 2010 Aug; 55(2):239-47. PubMed ID: 20582970
[TBL] [Abstract][Full Text] [Related]
4. Effective VCR/DEX pulse maintenance therapy in the KYCCSG ALL-02 protocol for pediatric acute lymphoblastic leukemia.
Okamoto Y; Koga Y; Inagaki J; Ozono S; Ueda K; Shimoura M; Itonaga N; Shinkoda Y; Moritake H; Nomura Y; Nakayama H; Hotta N; Hidaka Y; Shimonodan H; Suga N; Tanabe T; Nakashima K; Fukano R; Kawano Y
Int J Hematol; 2016 Feb; 103(2):202-9. PubMed ID: 26586463
[TBL] [Abstract][Full Text] [Related]
5. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial.
Conter V; Valsecchi MG; Silvestri D; Campbell M; Dibar E; Magyarosy E; Gadner H; Stary J; Benoit Y; Zimmermann M; Reiter A; Riehm H; Masera G; Schrappe M
Lancet; 2007 Jan; 369(9556):123-31. PubMed ID: 17223475
[TBL] [Abstract][Full Text] [Related]
6. [Report of Chinese Children's Cancer Group acute lymphoblastic leukemia 2015 multicenter study].
Chinese Children′s Cancer Group Acute Lymphoblastic Leukemia 2015 Study Group
Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1002-1010. PubMed ID: 36207846
[No Abstract] [Full Text] [Related]
7. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951.
De Moerloose B; Suciu S; Bertrand Y; Mazingue F; Robert A; Uyttebroeck A; Yakouben K; Ferster A; Margueritte G; Lutz P; Munzer M; Sirvent N; Norton L; Boutard P; Plantaz D; Millot F; Philippet P; Baila L; Benoit Y; Otten J;
Blood; 2010 Jul; 116(1):36-44. PubMed ID: 20407035
[TBL] [Abstract][Full Text] [Related]
8. Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932.
Angiolillo AL; Schore RJ; Kairalla JA; Devidas M; Rabin KR; Zweidler-McKay P; Borowitz MJ; Wood B; Carroll AJ; Heerema NA; Relling MV; Hitzler J; Lane AR; Maloney KW; Wang C; Bassal M; Carroll WL; Winick NJ; Raetz EA; Loh ML; Hunger SP
J Clin Oncol; 2021 May; 39(13):1437-1447. PubMed ID: 33411585
[TBL] [Abstract][Full Text] [Related]
9. Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3-PBX1 positive acute lymphoblastic leukaemia.
Wan Y; Zhang H; Zhang L; Cai J; Yu J; Hu S; Fang Y; Gao J; Jiang H; Yang M; Liang C; Jin R; Tian X; Ju X; Hu Q; Jiang H; Li H; Wang N; Sun L; Leung AWK; Wu X; Wang J; Li CK; Yang J; Tang J; Shen S; Zhai X; Pui CH; Zhu X
Br J Haematol; 2022 Nov; 199(4):587-596. PubMed ID: 36114009
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus retinitis as an adverse immunological effect of pulses of vincristine and dexamethasone in maintenance therapy for childhood acute lymphoblastic leukemia.
Moritake H; Kamimura S; Kojima H; Shimonodan H; Harada M; Sugimoto T; Nao-I N; Nunoi H
Pediatr Blood Cancer; 2013 Feb; 60(2):329-31. PubMed ID: 22976937
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
[TBL] [Abstract][Full Text] [Related]
12. Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5,659 children.
Eden T; Pieters R; Richards S;
Br J Haematol; 2010 Jun; 149(5):722-33. PubMed ID: 20331462
[TBL] [Abstract][Full Text] [Related]
13. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
14. Treatment of childhood acute lymphoblastic leukemia with protocol TCL-842 in Taiwan: the Taiwan Children's Cancer Study Group.
Yang CP; Lin ST; Liang DC; Hung IJ; Yang YM; Chen HN; Hsieh YL; Law KL; Lin MT; Twu BH
J Formos Med Assoc; 1993 May; 92(5):431-9. PubMed ID: 8104596
[TBL] [Abstract][Full Text] [Related]
15. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
[TBL] [Abstract][Full Text] [Related]
16. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
[TBL] [Abstract][Full Text] [Related]
17. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
[TBL] [Abstract][Full Text] [Related]
18. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
19. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
Veerman AJ; Kamps WA; van den Berg H; van den Berg E; Bökkerink JP; Bruin MC; van den Heuvel-Eibrink MM; Korbijn CM; Korthof ET; van der Pal K; Stijnen T; van Weel Sipman MH; van Weerden JF; van Wering ER; van der Does-van den Berg A;
Lancet Oncol; 2009 Oct; 10(10):957-66. PubMed ID: 19747876
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
